LB Pharmaceuticals Inc

NasdaqGM:LBRX Stock Report

Market Cap: US$1.5b

LB Pharmaceuticals Management

Management criteria checks 0/4

LB Pharmaceuticals' CEO is Heather Turner, appointed in Nov 2024, has a tenure of 1.83 years. total yearly compensation is $11.88M, comprised of 4.8% salary and 95.2% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth $3.28M. The average tenure of the management team and the board of directors is 0.7 years and 2.6 years respectively.

Key information

Heather Turner

Chief executive officer

US$11.9m

Total compensation

CEO salary percentage4.79%
CEO tenure1.8yrs
CEO ownership0.2%
Management average tenureless than a year
Board average tenure2.6yrs

Recent management updates

Recent updates

Analysis Article • May 16

LB Pharmaceuticals (NASDAQ:LBRX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

CEO Compensation Analysis

How has Heather Turner's remuneration changed compared to LB Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$86m

Mar 31 2026n/an/a

-US$39m

Dec 31 2025US$12mUS$569k

-US$25m

Sep 30 2025n/an/a

-US$19m

Jun 30 2025n/an/a

-US$29m

Mar 31 2025n/an/a

-US$52m

Dec 31 2024US$5mUS$69k

-US$63m

Compensation vs Market: Heather's total compensation ($USD11.88M) is above average for companies of similar size in the US market ($USD5.19M).

Compensation vs Earnings: Heather's compensation has increased whilst the company is unprofitable.

CEO

Heather Turner (53 yo)

1.8yrs
Tenure
US$11,884,985
Compensation

Ms. Heather D. Turner, J. D., Esq., is Chief Executive Officer and Director of LB Pharmaceuticals Inc from November 2024. She has been Independent Chairman of Avalyn Pharma Inc. since October 2024. She was...

Leadership Team

NamePositionTenureCompensationOwnership
Heather Turner
CEO & Director1.8yrsUS$11.88m0.21%
$ 3.3m
Gad Soffer
Chief Operating & Business Officerless than a yearUS$3.85m0.026%
$ 400.6k
Anna Eramo
Advisor6yrsUS$2.38m0.011%
$ 170.8k
Joseph Miller
Chief Financial Officerno datano datano data
Minako Pazdera
General Counselless than a yearno datano data
Lindsay Beaupre
Senior VP of People & Cultureless than a yearno datano data
Richard Silva
Senior Vice President of Technical Operations1.6yrsno datano data
James Rawls
Senior Vice President of Regulatory Affairsless than a yearno datano data
Ellen Rose
Senior Vice President of Corporate Affairsless than a yearno datano data
Kaya Pai Panandiker Kamlesh
Chief Commercial Officerless than a yearno datano data
Christopher Zergebel
Senior Vice President of Clinical Operationsless than a yearno datano data
0.7yrs
Average Tenure
51.5yo
Average Age

Experienced Management: LBRX's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Heather Turner
CEO & Director1.8yrsUS$11.88m0.21%
$ 3.3m
Robert Richard Ruffolo
Independent Director7.2yrsUS$365.00k0.0073%
$ 112.7k
John Kane
Chairman of Scientific Advisory Boardno datano datano data
Ran Nussbaum
Independent Director3.1yrsUS$246.51kno data
Maurizio Fava
Member of Scientific Advisory Boardno datano datano data
William Kane
Independent Director1yrUS$246.82kno data
Scott Garland
Independent Chairman of the Board2.6yrsUS$386.98k0.036%
$ 548.4k
Christoph Correll
Member of Scientific Advisory Board10.3yrsno datano data
Rebecca Luse
Independent Director3.1yrsUS$248.04kno data
Rekha Hemrajani
Independent Director1yrUS$252.91kno data
Robert Lenz
Independent Directorless than a yearno datano data
Luca Pani
Member of Scientific Advisory Boardno datano datano data
2.6yrs
Average Tenure
55.5yo
Average Age

Experienced Board: LBRX's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/10 23:57
End of Day Share Price 2026/09/10 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LB Pharmaceuticals Inc is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Malcolm HoffmanBMO Capital Markets Equity Research
Adam VogelCraig-Hallum Capital Group LLC
Raghuram SelvarajuH.C. Wainwright & Co.